AstraZeneca announced results from the Phase 3 ASCEND trial of Calquence in previously-treated patients with chronic lymphocytic leukaemia, or CLL. Results showed a statistically-significant and clinically-meaningful improvement in progression-free survival with Calquence monotherapy compared to a combination regimen of rituximab plus physician’s choice of idelalisib or bendamustine. “Importantly, the safety and tolerability of Calquence was consistent with the known profile,” the company stated. Calquence is currently approved for the treatment of adults with relapsed or refractory mantle cell lymphoma in the U.S., Brazil, the UAE, and Qatar, and is being developed for the treatment of CLL and other blood cancers. Jose Baselga, Executive Vice President, R&D Oncology said: “Calquence is the first BTK inhibitor to show benefit in a Phase III trial as a monotherapy compared to current standard-of-care combinations used in relapsed or refractory chronic lymphocytic leukaemia. We look forward to presenting detailed results at a forthcoming medical meeting.”
https://thefly.com/landingPageNews.php?id=2904001
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.